Deucravacitinib tablets | China Drugs List
Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.
- Company
- Bristol-Myers Squibb Pharma EEIG
- Medicine type
- Chemical medicine
- Therapeutic area
- Dermatology
- Indications recorded in the public source
- 1. Adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. 2. Adults with active psoriatic arthritis who responded inadequately to, or could not tolerate, a disease-modifying antirheumatic drug (DMARD).
- Indication source and scope
- Source date(s): 2026-06-15. Additional indications may be supported by newer announcements or submissions rather than the older full label; see the indication sources.
- Prescribing-information limitations
- Official prescribing-information link located; the document body has not yet been verified.
- China availability status
- Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- Overseas status
- Japan, United Kingdom: local approval / launch announcements and official price sources obtained. Indications and dates are specified in each price record; other markets not exhaustively reviewed.
- Insurance classification
- Included in national insurance (Category B)
- Insurance edition
- 2025 edition; effective 1 January 2026
- Insurance restrictions
- Limited to adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
- Insurance period
- 2025-01-01 to 2026-12-31
- Insurance verification notes
- Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.
Sources
- https://www.nmpa.gov.cn/directory/web/nmpa/images/1707039824076019627.pdf
- https://www.nhsa.gov.cn/module/download/downfile.jsp?classid=0&filename=a32f9f2f3fc046afaf08471f87456ce3.pdf
- https://www.bms.com/cn/media/press-release-listing/07062026.html
Open the interactive record, public price references and discussions